<DOC>
	<DOCNO>NCT00385203</DOCNO>
	<brief_summary>To determine anti-tumour activity biological effect cediranib ( AZD2171 ) dose 45mg , primarily Gastrointestinal Stromal Tumour ( GIST ) patient resistant imatinib mesylate ( current standard therapy ) also patient metastatic Soft Tissue Sarcoma ( STS ) resistant standard therapy .</brief_summary>
	<brief_title>The Biological Activity Cediranib ( AZD2171 ) Gastro-Intestinal Stromal Tumours ( GIST ) .</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histological cytological confirmation GIST resistant intolerant imatinib mesylate , metastatic STS , refractory standard therapy standard therapy exist Patients type I insulindependent diabetes poorlycontrolled type II insulinindependent diabetes . Patients history poorly control high blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Metastatic Gastro-Intestinal Stromal Tumours</keyword>
	<keyword>gastro-intestinal cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>